Wird geladen...
Chemotherapy re-challenge response rate in metastatic colorectal cancer
BACKGROUND: There are few treatment options in metastatic colorectal cancer (mCRC) after progression on standard chemotherapy. Third and fourth line therapies typically consist of regorafenib or trifluridine-tipiracil, however, clinical benefit of these medications is limited, as progression free su...
Gespeichert in:
| Veröffentlicht in: | J Gastrointest Oncol |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
AME Publishing Company
2018
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6087874/ https://ncbi.nlm.nih.gov/pubmed/30151264 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2018.04.08 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|